Imugene Ltd has released a press release.
Third response in concurrent BTKi Cohort of azer-cel Trial
Earlier from Imugene
- $11.1 Million Placement Completed to Advance azer-cel
- New Complete Response in the Concurrent BTKi azer-cel Cohort
- First Complete Response in Concurrent BTKi azer-cel Cohort
- Azer-cel Granted FDA Fast Track Designation for CLL and MZL